Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins
Boston Scientific reported Q3 sales of $5.065 billion, up 20.3% year-over-year, and adjusted EPS of $0.75, beating forecasts. The company raised its 2025 adjusted EPS guidance to $3.02–$3.04, above consensus. Shares rose about 4% in pre-market trading Oct. 22. U.S. sales jumped 27%, led by strong cardiovascular device demand.